


REMARKS

In response to the Restriction Requirement dated February 19, 2004, applicants have elected with traverse, the species Ribi Adjuvant system based adjuvants, for examination at this time. Applicants reserve the right to pursue, without prejudice, the subject matter of the non-elected groups and/or species in a subsequent divisional, continuation and/or continuation-in-part application.

Applicants respectfully request that the Examiner consider examining the non-specific immune response enhancers recited in claims 105 and 107 as well as the elected species, Ribi Adjuvant system based adjuvants, in a single application. The non-specific immune response enhancers recited in claims 105 and 107 are related one to the other in that each of the recited compounds is, as the generic claim suggests, a non-specific immune response enhancer. Applicants submit that it would not be an undue burden on the Examiner to search the subject matter recited in claims 105 and 107.

Consideration of the elected claims is now requested.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Julie A. Urvater, Ph.D., Patent Agent
Registration No. 50,461

JAU:tt
Enclosure:
Postcard

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031
463580_1.DOC